ShambaviDRichardMD

Oncology • New York, NY

Physician

Join to view full profile

Dr. Richard is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Richard's full profile

Already have an account?

Office
325 W 15th St
New York, NY 10011
Phone+1 212-604-6021

Fax+1 201-418-9118

Education & Training

Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 1997 - 1998
BronxCare Health SystemResidency, Internal Medicine, 1992 - 1995
Stanley Medical College SMCClass of 1988

Certifications & Licensure

NY State Medical License 1995 - 2026
NJ State Medical License 2004 - 2021

Publications & Presentations

PubMed

Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.
Doris K Hansen, Lauren C Peres, Danai Dima, Alicia Richards, Leyla Shune
Journal of Clinical Oncology. 2025-02-18
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class ...
Gayathri Ravi, Shambavi Richard, Shaji Kumar, Shebli Atrash, Michaela Liedtke
Leukemia. 2025-02-05
MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma.
Lucia Y Chen, Santiago Thibaud, Saoirse Bodnar, Ajai Chari, Joshua Richter
Blood Advances. 2025-01-14

Abstracts/Posters

Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance
Shambavi Richard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

CAR-T Destined for Earlier Lines of Therapy in Blood Cancers, Experts SayNovember 18th, 2022